megakaryocytic


Also found in: Wikipedia.
Related to megakaryocytic: megakaryocytic leukemia

megakaryocytic

(ˌmɛɡəˌkærɪəˈsɪtɪk)
adj
(Physiology) relating to, designating, or involving megakaryocytes
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
ThesaurusAntonymsRelated WordsSynonymsLegend:
Adj.1.megakaryocytic - of or pertaining to large bone marrow cellsmegakaryocytic - of or pertaining to large bone marrow cells
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
References in periodicals archive ?
These cases predict more reticulin fibrosis, occasional megakaryocytic clustering with atypia, and erythroid and megakaryocytic hyperplasia (95).
Bone marrow aspirate revealed hypercellular marrow with marked depletion of all three elements, i.e., erythroid, myeloid and megakaryocytic. 80% cells were blasts, morphologically similar to peripheral smear blasts with high nuclear to cytoplasmic ratio, scanty to moderate cytoplasm and inconspicuous nucleoli.
Lineage-specific markers, including myeloid (CD13, CD33, CD117, MPO), monocytic (CD11b, CD14, CD64), megakaryocytic (CD61), B-cell (CD19, CD10, CD20) and T-cell (CD3) antigens, were negative.
(37,38,40) The presence of megakaryocytic dysplasia may pose a diagnostic challenge to differentiation of thrombocytopenia in the setting of germline ANKRD26 mutation versus MDS.
Both the congenital syndromic SA patients showed megakaryocytic hypoplasia and dysplasia of the myeloid and erythroid lines indicating a more generalized pathology.
Bone marrow examination (BME) showed hypocellularity in the myeloid and megakaryocytic series.
A diagnosis of AML can be made based on (1) [greater than or equal to]20% blasts of myeloid and/or monocytic or megakaryocytic lineages and (2) the presence of recurrent cytogenetic abnormalities, including t(8;21) (q22;q22.1), inv16(p13.1q22), or t(16;16) (p13.1:q22) and PML-RARA fusion (1).
Mulpleta is an orally bioavailable, small molecule TPO receptor agonist that interacts with the transmembrane domain of human TPO receptors expressed on megakaryocytes to induce the proliferation and differentiation of megakaryocytic progenitor cells from hematopoietic stem cells and megakaryocyte maturation.
(A serum methotrexate level below approximately 0.02 [micro]-Mol/L has been indicated as necessary for resumption of DNA synthesis.) A bone marrow biopsy revealed hypocellular bone marrow, with a marrow-tofat ratio of 20:80 and trilinear panhypoplasia of the erythroid, myeloid, and megakaryocytic cell lines; no metastatic tumor or granuloma was seen.
Myeloproliferative disorders are characterized by purposeless proliferation of one or more of nonlymphoid marrow cell lines (granulocytic, monocytic, erythrocytic or megakaryocytic) (Harvey, 2001).
Note granularity and mononuclearity of megakaryocytic (B), binuclearity of erythroid precursors (C) and pseudo Pelger-Huet (D).
also showed that survivin is definitely required for megakaryocytic and erythroid progenitors' development, although its expression diminishes in terminal stages of megakaryocytes' differentiation [7].